Table 3

Logistic regression models for the association between Anti-CarP specificities with RA-ILD

Main populationReplication sample
ORp>|z|95% CIORp>|z|95% CI
Anti-FCS3.4210.0301.125 to 10.40410.4190.0121.684 to 64.459
 Age1.0680.0081.017 to 1.1201.0450.2110.974 to 1.122
 RA disease duration1.2910.0001.161 to 1.4360.9890.7080.933 to 1.047
 ACPA0.5250.3000.155 to 1.7750.7080.8090.043 to 11.624
 RF2.0160.2460.616 to 6.5965.0800.0800.823 to 31.330
 Sex0.4920.2010.166 to 1.4593.5940.1280.692 to 18.670
 Smoking cumulative dose1.0230.1450.992 to 1.0550.9620.0610.923 to 1.001
Anti-Fib2.8460.0950 .834 to 9.7081.6490.4910.396 to 6.856
 Age1.0700.0061.020 to 1.1231.0470.1420.984 to 1.115
 RA disease duration1.2760.0001.147 to 1.4200.9830.5180.934 to 1.034
 ACPA0.6180.4270.188 to 2.0261.7680.6410.160 to 19.419
 RF1.6880.4310.459 to 6.2125.6130.0560.956 to 32.952
 Sex0.4750.1790.160 to 1.4082.4060.2290.575 to 10.066
 Smoking cumulative dose1.0260.0890.996 to 1.0570.9690.0830.935 to 1.004
Anti-CFFHP3.1150.0391.061 to 9.1381.4940.5340.421 to 5.291
 Age1.0580.0161.010 to 1.1071.0460.1470.984 to 1.113
 RA disease duration1.2850.0001.157 to 1.4260.9850.5860.937 to 1.037
 ACPA0.4940.2680.142 to 1.7201.8680.6050.174 to 19.948
 RF2.6170.1040.819 to 8.3576.2310.0371.113 to 34.888
 Sex0.3820.0920.124 to 1.1712.0300.3210.501 to 8.215
 Smoking cumulative dose1.0230.1430.992 to 1.0550.9710.1260.937 to 1.008
  • ACPA, anticitrullinated protein antibody; Anti-CarP, anti-carbamylated protein antibodies; Anti-CFFHP, IgG antibodies against chimeric fibrine/filagrine homocitrullinated peptide; Anti-FCS, IgG antibodies against carbamylated fetal calf serum; Anti-Fib, IgG antibodies against carbamylated fibrinogen; ILD, interstitial lung disease; RA, rheumatoid arthritis; RF, rheumatoid factor.